医学
中性粒细胞减少症
内科学
发热性中性粒细胞减少症
白细胞减少症
中性粒细胞绝对计数
胃肠病学
不利影响
临床试验
菌血症
粘膜炎
外科
作者
Yasunori Nakagawa,Kenshi Suzuki,Takayuki Hirose,Takaaki Chou,Shin Fujisawa,Michiko Kida,Kensuke Usuki,Yoji Ishida,Shuichi Taniguchi,Yasuji Kouzai,Shigeru Tomoyasu,Koji Miyazaki,Masaaki Higashihara,Kiyoshi Ando,Sadao Aoki,Ayako Arai,Nobu Akiyama,Kiyohiko Hatake,Shinichiro Okamoto,Kazuo Dan,Kazuma Ohyashiki,Urabe A
标识
DOI:10.1007/s10156-010-0075-3
摘要
A multi-institutional study was conducted to assess efficacy and safety of biapenem (BIPM), a carbapenem antibiotic, as an initial-stage therapeutic agent for febrile neutropenia (FN) in patients with hematopoietic diseases. A total of 216 patients from 25 medical institutions were enrolled in this study; of these, 204 were included in the safety analysis and 178 in the efficacy analysis. The combined (excellent and good) response rate was 67.9%, and antipyretic effect (subsidence + tendency to subsidence) was achieved within 3 and 5 days of treatment in 67.3 and 75.9% of patients, respectively. Thus, the clinical responses were gratifying. A response rate of 61.7% (37/60) was observed even in high-risk FN patients in whom neutrophil counts prior to and at 72 h after the start of BIPM were ≤100/μl. BIPM is considered to be a highly promising drug, with prompt onset of clinical benefit, as an initial-stage therapeutic agent for the treatment of FN in patients with hematopoietic diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI